Categories Analysis, Earnings, Health Care, LATEST

Earnings Preview: GW Pharma to widen losses in to-be-reported quarter

GW Pharmaceuticals PLC (GWPH) is expected to post its quarterly earnings on Feb. 26.

Last week, GW Pharma saw its stock slide 1.32% in a day to close at $143.95 on Wednesday. But when it opened for trading the very next day, it was to be noted that shares had grown 7.5% in a month. This growth has clearly outpaced the medical sector which moved up just 3% in the same period.

GW Pharma is expected to post a quarterly loss of $2.97 per share, indicating a 22% slide from same time a year ago, on revenue of $7.10 million. However, this could see a change given that the company is shifting its earnings reporting to a new fiscal year-ending Dec. 31, 2018.

Investing in pot stocks 101: Here’s what you should know

LOOKING BACK

In the previously reported fourth quarter of the last fiscal cycle, GW Pharma stock slipped 4% in after-hours trading after the company missed analyst estimates for the period. Sales for the biopharma firm dipped 1% to $2.42 million on flat product sales, and revenues failed to beat street consensus.

The company’s loss widened 28% to $0.23 per share, on increased selling, general and administrative (SG&A) expenses.

On Nov. 26, GW’s frontline cannabinoid drug Epidiolex posted positive results in the second Phase-3 trial for treating patients diagnosed with the Dravet syndrome, a rare form of epilepsy which causes seizures right from childhood. It is estimated that there are 2.2 million people in the US who suffer from epilepsy and nearly 470,000 are children.

Epidiolex was approved by the US FDA in June 2018 to treat patients suffering from seizures relating to Dravet syndrome or Lennox-Gastaut syndrome (LGS). The company filed a marketing authorization application with the European Medicines Agency (EMA) and expects to receive approval from the regulator by the first quarter of 2019.

Epidiolex competes with Fintepla from Zogenix (ZGNX). Fintepla is a low-dose fenfluramine formulation drug to treat patients with Dravet syndrome. Zogenix has kickstarted the rolling submission of new drug application filing to FDA for treating patients with the Dravet syndrome. The low-dose fenfluramine drug has also shown positive results in LGS with Zogenix is currently enrolling patients for phase 3 clinical trial of Fintepla for patients diagnosed with LGS.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Infographic: Nvidia (NVDA) Q4 revenue up 61%; earnings beat

Nvidia Corporation (NASDAQ: NVDA) Wednesday said its fourth-quarter revenues and profit increased in double-digits amid elevated demand. The results also topped the Street view, driving the stock higher during the

Nutanix (NTNX) Earnings: 2Q21 Key Numbers

Nutanix (NASDAQ: NTNX) reported second quarter 2021 earnings results today. Total revenue remained flat at $346.4 million compared to the same period a year ago. GAAP net loss was $287.3

Macy’s (M) expects digital channels to generate approx. $10 billion in sales by 2023

Shares of Macy’s Inc. (NYSE: M) were down 2.7% in morning trade on Wednesday. The stock has gained 37% since the beginning of the year. A day ago, the retailer

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top